Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
No consensus guidelines exist for management of post-transplant glucocorticoid induced hyperglycemia, but most published reviews recommend insulin as first line therapy. A variety of insulin regimens have been proposed, including mealtime short-acting regular or analog insulin, once daily neutral protamine hagedorn (NPH) insulin, pre-mixed insulin, or basal insulin alone such as glargine or detemir. However, no randomized trial has ever examined different insulin regimens to determine which most effectively controls post-transplant steroid-induced hyperglycemia. Consequently, the proposed study intends to examine three commonly used insulin regimens used for managing post-transplant once-daily glucocorticoid-induced hyperglycemia to determine which is most effective:
Question/Hypothesis:
Among three commonly used insulin regimens, which is most effective for managing post-transplant once-daily glucocorticoid-induced hyperglycemia?
Inclusion Criteria:
Have undergone bone marrow, liver, lung, or renal transplant.
Be using once daily oral glucocorticoid therapy (total daily dose of Prednisone ≥10 mg, Hydrocortisone ≥40 mg, Dexamethasone ≥1.5 mg) administered in the morning and expected to continue for at least 2 weeks.
Have pre-existing or newly diagnosed diabetes mellitus established by any of the criteria listed below:
Have at least three pre-meal inpatient capillary blood glucose (CBG) readings ≥ 7.8 mmol/L
Be eating meals by mouth
Exclusion Criteria: